Debt-to-equity of OptimizeRx Corp from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
OptimizeRx Corp quarterly Debt-to-equity in % history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • OptimizeRx Corp Debt-to-equity for the quarter ending 30 Sep 2025 was 43%, a 2.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

OptimizeRx Corp Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 43% -1.1% -2.5% 30 Sep 2025
Q2 2025 44% +9.2% +26% 30 Jun 2025
Q1 2025 44% +19% +72% 31 Mar 2025
Q4 2024 44% +28% +175% 31 Dec 2024
Q3 2024 44% +38% +617% 30 Sep 2024
Q2 2024 35% +29% +518% 30 Jun 2024
Q1 2024 26% +20% +359% 31 Mar 2024
Q4 2023 16% +11% +198% 31 Dec 2023
Q3 2023 6.1% +0.58% +10% 30 Sep 2023
Q2 2023 5.7% -0.21% -3.6% 30 Jun 2023
Q1 2023 5.6% -0.51% -8.3% 31 Mar 2023
Q4 2022 5.4% -0.55% -9.2% 31 Dec 2022
Q3 2022 5.6% -1.7% -24% 30 Sep 2022
Q2 2022 5.9% -3.3% -36% 30 Jun 2022
Q1 2022 6.1% -8% -57% 31 Mar 2022
Q4 2021 6% -18% -75% 31 Dec 2021
Q3 2021 7.3% -18% -71% 30 Sep 2021
Q2 2021 9.2% -16% -64% 30 Jun 2021
Q1 2021 14% -8.9% -39% 31 Mar 2021
Q4 2020 24% +1.7% +7.7% 31 Dec 2020
Q3 2020 25% +2.6% +12% 30 Sep 2020
Q2 2020 26% 30 Jun 2020
Q1 2020 23% 31 Mar 2020
Q4 2019 22% 31 Dec 2019
Q3 2019 23% 30 Sep 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.